Pb-212 has a 10.6-hour half-life. A shipment from Ontario arrives with less than half its activity intact. Radia Theranostics is building Western Canada's first dedicated, GMP-controlled Pb-212 manufacturing platform to close that gap.
Targeted alpha therapy (TAT) using Lead-212 is at the forefront of cancer treatment. But Pb-212's short half-life creates a logistics constraint that large centralized facilities are physically incapable of solving.
Alpha particles deliver 50–100× the cell-killing energy of beta emitters, with a path length measured in microns — destroying tumour cells while sparing surrounding healthy tissue with unprecedented precision.
Alpha particles travel only 40–80 µm in tissue — roughly 5–10 cell diameters. Targeted delivery means maximum cytotoxicity at the tumour site, minimal systemic dose.
Pb-212 acts as an in-vivo generator, delivering its daughter Bi-212 directly at the tumour site. This two-step radiobiology maximizes therapeutic efficacy without systemic alpha exposure during delivery.
Pb-212's SPECT-imageable decay product, Pb-203, enables a matched diagnostic-therapeutic pair — the same vector, same pharmacokinetics. True theranostics: image, then treat.
A capital-efficient, purpose-built radioisotope manufacturing platform designed from the ground up for CNSC licensing and Health Canada GMP compliance — with a total build cost a fraction of centralized alternatives.
No GMP-qualified Pb-212 manufacturing facility exists anywhere west of Ontario. The table below shows what Western Canadian clinical partners currently face when seeking Pb-212 supply — and what Radia is being built to provide.
Radia Theranostics is currently in its facility build and qualification phase. First GMP commercial production is targeted following Health Canada Drug Establishment Licence approval, anticipated in Year 2 of operations. Clinical partners and trial sponsors are encouraged to engage now — anchor supply agreements entered during the build phase will directly inform production scheduling and capacity allocation.
| Existing Options for Western Canadian Clinical Partners | GMP BC Facility | Health Canada Reg. | Activity-Viable Western CA Delivery | Canadian IND Supply |
|---|---|---|---|---|
| Radia Theranostics — In Development · BC — Site Selection Underway | In Dev. | In Dev. | Planned ✓ | Planned ✓ |
| Orano Med ATLab (Indianapolis, USA) | ✗ US only | ✗ FDA only | ✗ Trans-border | Partial |
| AtomVie (Hamilton, ON) | ✗ Ontario | ✓ | ✗ >50% activity lost in transit | ✓ Not Pb-212 |
| BWXT Medical (Ottawa, ON) | ✗ Ontario | ✓ | ✗ >50% activity lost in transit | ✓ Not Pb-212 |
| Import (any US facility) | Various | ✗ | ✗ | ✗ |
Table reflects current landscape as of mid-2026. Radia's planned capabilities are subject to regulatory approval and build timeline. "Canadian IND Supply" refers to Health Canada IND-compliant GMP Pb-212 isotope supply specifically.
Radia's founding team combines direct Pb-212 and alpha-isotope operating experience with GMP facility expertise, financial management, and dual CNSC/Health Canada regulatory knowledge — rare capabilities that converge in one place.
Radia is supported by an internationally recognized scientific and clinical advisory board whose combined expertise spans the full value chain of targeted alpha therapy — from isotope production through to first-in-human clinical trials.
Collectively, the board brings direct experience in Pb-212, Ac-225, At-211, and Lu-177 isotope production; cyclotron and generator-based manufacturing at commercial scale; GMP radiopharmaceutical CMC development and regulatory submissions across Health Canada, FDA, and EMA frameworks; nuclear medicine clinical leadership at major North American and Asian academic medical centres; cold-chain logistics for short half-life isotopes across BC and North America; and principal investigator experience on first-in-human alpha therapy trials in PSMA-targeted and thyroid cancer indications. Their involvement directly informs Radia's production methodology, regulatory strategy, and clinical partner development.
We are actively engaging clinical partners, trial sponsors, and institutional collaborators ahead of our first production release. If your programme requires a Western Canadian GMP Pb-212 supplier, we want to hear from you.
✓ Thank you — your inquiry has been received. A member of our team will be in touch within two business days.